Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMC-A12 +/- Cetuximab in mCRC
NCT00503685Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2007
- Primary completion
- Mar 2009
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cixutumumab in metastatic colorectal cancer (mCRC), sponsored by Eli Lilly and Company. Started Jun 2007; status: completed.
02
Drugs
cixutumumab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT00503685.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00503685.